Prof. Fischer

Prof. Dr. med. Thomas Fischer
Zentrum für Innere Medizin (ZIM): Universitätsklinik für Hämatologie und Onkologie (KHAE)
Fax: +49 391 67 13267
Prof. Dr. med. Thomas Fischer

Zentrum für Innere Medizin (ZIM): Universitätsklinik für Hämatologie und Onkologie (KHAE)
Fax: +49 391 67 13267
Aktuelle Projekte
- TeleBlut - Individualisierte Anämie- und Polyzythämie- Früherkennung
Laufzeit: 01.04.2016 - 31.03.2019
Abgeschlossene Projekte
- Dysregulation of integrin function and induction of inflammation in JAK2-mutated myeloproliferative neoplasia.
Laufzeit: 01.01.2014 - 31.12.2017 - Identifizierung neuer Zielmoleküle für die klinische Therapie der akuten myeloischen Leukämie (AML)
Laufzeit: 01.07.2014 - 30.06.2017 - Understanding misbalanced signalling by JAK2-V617F in myloproliferative neoplasms fusing qualitative and quantitative modelling
Laufzeit: 01.01.2013 - 31.12.2015 - Aberrante Aktivierung der Signaltransduktion durch differentielle Protein-Protein-Interaktion von mutierten FLT3-Rezeptoren
Laufzeit: 01.03.2010 - 31.12.2014 - Identifizierung und funktionelle Charakterisierung von onkogenen Kinase-Signalkaskaden bei der FLT3-ITD-positiven akuten myeloischen Leukämie (AML).
Laufzeit: 01.10.2009 - 31.12.2012 - Moguntinone als neue Therapieoption bei Malignomen
Laufzeit: 01.05.2009 - 30.04.2012 - Differentielle Signaltransduktion von FLT3- Rezeptoren mit atypischen, non- juxtamembranären ITD-Mutationen
Laufzeit: 01.07.2008 - 30.06.2011 - Funktionelle Charakterisierung von onkogenen Signaltransduktionswegen in Weichgewebssarkomen
Laufzeit: 01.07.2008 - 30.06.2011 - Vergleichende Kinomanalyse in CD34-positiven hämatopoetischen Zellen von Patienten mit JAK2V617F-positiven myeloproliferativen Erkrankungen
Laufzeit: 01.10.2007 - 30.09.2009 - Untersuchungen zur primären Resistenz von leukämischen Blasten der akuten myeloischen Leukämie (AML) auf FLT3-Tyrosinkinase-Inhibitoren (FLT3-TKI)
Laufzeit: 01.01.2006 - 30.06.2009
2018
Begutachteter Zeitschriftenartikel
Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 32.2018, 3, S. 846-849; http://dx.doi.org/10.1038/leu.2017.324
2017
Abstrakt
Variant allele frequency kinetics of tyrosine kinase gene mutations in core-binding factor acute myeoloid leukemia (CBF-AML) under treatment with and without dasatinib
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata-Storti Foundation, Bd. 102.2017, Suppl. 2, P535, S. 204-205; http://www.haematologica.org/content/102/s2/1.full.pdf+html
CTLA-4 mediated effects on STATs regulate differentiation and plasticity of Tc17 cells
In: European journal of immunology - Weinheim: Wiley VCH, Bd. 47.2017, Suppl. 2, P395, S. 277; http://dx.doi.org/10.1002/eji.201770300
Preclinical evaluation of immuno-/proteasome inhibitors in soft-tissue sarcoma
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, V415, S. 111-112; https://www.karger.com/Article/Abstract/479566
Three cases of herpes virus reactivation after allogeneic stem cell transplantation
In: Bone marrow transplantation - London: Springer Nature, Bd. 52.2017, Suppl. 1, S. S268; http://www.ebmt2017.org/poster-abstracts
Epidemiological, genetic and clinical characterization of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) (NCT01252485)
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, P198, S. 45-46; https://www.karger.com/Article/Abstract/479566
NFKB pathway promotes tumor progression through Brutons tyrosine kinase in MLL+ acute myeloid leukemia
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata-Storti Foundation, Bd. 102.2017, Suppl. 2, E865, S. 356-357
A simple prognostic index for prediction of central venous catheter-related bloodstream infections in patients with haematological malignancies (CIPS-H)
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, V765, S. 222; https://www.karger.com/Article/Abstract/479566
Impact of treatment delay on prognosis in patients with primary CNS lymphoma
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, P282, S. 77; https://www.karger.com/Article/Abstract/479566
Early death in patients with primary CNS lymphoma
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, P281, S. 76; https://www.karger.com/Article/Abstract/479566
Begutachteter Zeitschriftenartikel
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs
In: OncoImmunology - Austin, Tex: Landes Bioscience, Bd. 6.2017, 2, Art.-Nr. e1273300, insges. 5 S.; http://dx.doi.org/10.1080/2162402X.2016.1273300
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells
In: Cellular signalling - Amsterdam [u.a.]: Elsevier Science, Bd. 35.2017, S. 37-47; http://dx.doi.org/10.1016/j.cellsig.2017.03.021
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma - DSMM XI trial
In: British journal of haematology: the official journal of the British Society for Haematology and the European Haematology Association - Oxford [u.a.]: Wiley-Blackwell, Bd. 179.2017, 4, S. 586-597; http://dx.doi.org/10.1111/bjh.14920
Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 6, S. 1463-1466; http://dx.doi.org/10.1038/leu.2017.83
RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts
In: Cell death and differentiation - Houndmills, Basingstoke: Nature Publishing Group, Bd. 24.2017, 2, S. 371-383; http://dx.doi.org/10.1038/cdd.2016.141
JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 5, S. 1223-1226; http://dx.doi.org/10.1038/leu.2017.26
Gain of function in Jak2V617F positive T-cells. Letter to the editor
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 4, S. 1000-1003; http://dx.doi.org/10.1038/leu.2017.6
Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells
In: Nature Communications - [London]: Nature Publishing Group UK, Bd. 8.2017, Art.-Nr. 311, insges. 16 S.; http://dx.doi.org/10.1038/s41467-017-00169-4
Determination of a cutoff time point for prophylactic exchange of central venous catheters for prevention of central venous catheterrelated bloodstream infections in patients with hematological malignancies
In: Infection control and hospital epidemiology: the official journal of the Society for Healthcare Epidemiology of America - Cambridge: Cambridge Univ. Press, Bd. 38.2017, 7, S. 888-889; http://dx.doi.org/10.1017/ice.2017.92
Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma - Letter to the editor
In: European journal of cancer - Amsterdam [u.a.]: Elsevier, Bd. 75.2017, S. 280-283; http://dx.doi.org/10.1016/j.ejca.2016.11.035
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia - letter to the editor
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 5, S. 1217-1220; http://dx.doi.org/10.1038/leu.2017.22
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
In: Journal of cancer research and clinical oncology: official organ of the Deutsche Krebsgesellschaft - Berlin: Springer, Bd. 143.2017, 5, S. 807-820; http://dx.doi.org/10.1007/s00432-017-2354-1
Diagnostic and therapeutic challenges in extragonadal yolk sac tumor with hepatoid differentiation - a case report
In: Molecular and clinical oncology: an international journal devoted to oncology - Athens: Spandidos Publ, Bd. 6.2017, 1, S. 79-82; http://dx.doi.org/10.3892/mco.2016.1080
Buchbeitrag
Tumor-Lyse-Syndrom
In: Gastroenterologie für Intensivmediziner: 68 Abbildungen - Stuttgart: Georg Thieme Verlag, S. 196-199, 2017
2016
Abstrakt
Research and science
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Seite 326
Effectiveness of tigecycline (TGC) in hematological patients (pts) with persisting or recurring fever - a retrospective, monocentric review of 78 cases
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P957, Seite 296
Characteristics and treatment of sarcoma patients in a single-center analysis
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P917, Seite 279-280
Expression level of JAK2-V617F determines sensitivity to tyrosine kinase inhibitor Ruxolitinib in HEK293 Flp-In cells and can be augmented by treatment with inhibitors of PI3K/Akt pathway in JAK2-V617F - positive murine progenitor cells
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P510, Seite 148-149
LPS stimulation induces ROS formation, apoptosis, DNA damage and oxidation of cysteine residues in FLT3-ITD positive cell lines resulting in FLT3-tyrosine kinase inhibitor resistance
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 101.2016, s1, Abs. E877, S. 360
Reactive oxygen species (ROS) modulates sensitivity to FLT3-tyrosine kinase inhibitors in murine and human FLT3-ITD positive AML cell lines
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 101.2016, s1, Abs. E885, S. 362-363
Regulatory role of intracellular ROS levels and effects of antioxidants (NAC, Tempol) on proliferation, cell cycle and sensitivity to treatment with tyrosine kinase inhibitor Ruxolitinib in JAK2-V617F - positive myeloproliferative neoplasms
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P509, Seite 148
Prophylactic exchange of central venous catheters (CVC) for prevention of CVC-related bloodstream infections (CRBSI) in patients with haematological malignancies: indirect evidence from pooled data of the SECRECY registry and the COAT study
In: Oncology research and treatment. - Basel : Karger; Bd. 39 (2016), Suppl.3, Abs. V44, Seite 8
Cell intrinsic induction of IP-10 in MPN
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. V107, Seite 26
Randomized comparison of pegylated IFN-a2b versus IFN-a2b maintenance following tandem autologous transplant in multiple myeloma
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P546, Seite 163
Artikel in Zeitschrift
Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia - a study of the East German Haematology and Oncology Study Group (OSHO)
In: Journal of cancer research and clinical oncology: official organ of the Deutsche Krebsgesellschaft - Berlin: Springer, Bd. 142.2016, 1, S. 305-315; http://dx.doi.org/10.1007/s00432-015-2045-8
Begutachteter Zeitschriftenartikel
Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo
In: Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal. - Basingstoke : Nature Publ. Group, Bd. 30.2016, 5, S. 1220-1225
Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata Storti Foundation; Bd. 101.2016, 3, S. e81-e85
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger) - a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
In: The lancet <London>. - London [u.a.] : Elsevier, Bd. 388.2016, 10044, S. 565-575
Leukemogenic potency of the novel FLT3-N676K mutant
In: Annals of hematology : organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie. - Berlin : Springer, Bd. 95.2016, 5, S. 783-791
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD positive AML cells
In: Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal. - Basingstoke : Nature Publ. Group, Bd. 30.2016, 2, S. 473-483
Optimum experimental design for patient specific mathematical leukopenia models
In: IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 344-349, 49 2016 26 344-349; http://dx.doi.org/10.1016/j.ifacol.2016.12.150 ; [Kongress: Foundations of Systems Biology in Engineering, FOSBE 2016, Magdeburg, Germany, 9-12 October, 2016]
Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias - letter to the editor
In: Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal. - Basingstoke : Nature Publ. Group, Bd. 30.2016, 10, S. 2090-2093
Kinomics screening identifies aberrant phosphorylation of CDC25C in FLT3-ITD-positive AML
In: Anticancer research : international journal of cancer research and treatment. - Attiki, Bd. 36.2016, 12, S. 6249-6258
Parameter estimation for leukocyte dynamics after chemotherapy
In: IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 44-49; http://dx.doi.org/10.1016/j.ifacol.2016.12.101 ; [Kongress: Foundations of Systems Biology in Engineering, FOSBE 2016, Magdeburg, Germany, 9-12 October, 2016]
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma - an analysis of the German Hodgkin-Study Group
In: Leukemia and lymphoma. - London [u.a.] : Taylor &amp;amp;amp;amp;amp; Francis Group, Bd. 57.2016, 5, S. 1067-1073
Biased low incidence of central venous catheter-related bloodstream infections in controlled clinical trials? - letter to the editor
In: Infection control and hospital epidemiology : the official journal of the Society for Healthcare Epidemiology of America. - Cambridge : Cambridge Univ. Press, Bd. 37.2016, 5, S. 617-619
Hemophagocytic lymphohistiocytosis as an unusual cause of prolonged bicytopenia after chemotherapy
In: Clinical Case Reports. - Chichester : Wiley, Bd. 4.2016, 10, S. 1017-1018
Characteristics and outcome of patients with primary CNS lymphoma in a real-life setting compared to a clinical trial
In: Annals of hematology : organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie. - Berlin : Springer, Bd. 95.2016, 5, S. 793-799
Buchbeitrag
Verminderung der magnetischen Nahfeldeinkopplung auf Leiterplattenebene durch reziproke Systemanalysen
In: EMV 2016 : Internationale Fachmesse und Kongress für Elektromagnetische Verträglichkeit : Düsseldorf, 23. - 25.02.2016. - Aachen : Apprimus Verlag, S. 669-676 ; [Kongress: EMV 2016, Internationale Fachmesse und Kongress für Elektromagnetische Verträglichkeit, Düsseldorf, 23. - 25.02.2016]
Nicht begutachteter Zeitschriftenartikel
Das internistische Jahr 2015 - die wichtigsten Fortschritte und Entwicklungen
In: Ärzteblatt Sachsen-Anhalt : offizielles Mitteilungsblatt der Ärztekammer Sachsen-Anhalt. - Magdeburg : Ärztekammer Sachsen-Anhalt, Bd. 27.2016, 5, S. 19-22
2015
Abstrakt
Requirement for phospholipase C gamma 1 (PLCG1) in development and maintenance of hematopoietic stem- and progenitor cells
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 100.2015, Suppl. 1, Abs. E1133, S. 452
Results from two phase 3 studies of post-transplant bortezomib (BTZ) consolidation vs observation (OBS) in patients with newly diagnosed multiple myeloma (NDMM)
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 100.2015, Suppl. 1, Abs. S426, S. 151
The novel FLT3-N676K mutant induces acute leukemia independently of the Inv(16) chimeric gene CBFB-MYH11
In: Blood : journal of the American Society of Hematology. - Stanford, Calif : HighWire Press, Bd. 126.2015, 23, S. 1383
Psycho-oncologic interventions for parents of cancer patients - systematic review
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V565, S. 172
The somatic burden score - a quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V630, S. 192
Distinct and non-overlapping functions of LLGL1 and scribble in hematopoietic stem cells
In: Experimental hematology : official publication of the International Society for Experimental Hematology. - Kidlington [u.a] : Elsevier; Bd. 43.2015, 9 Suppl., Abs. 3065, S. S67
Delayed entry of blood cultures into blood culture incubators has no negative effect of on overall culture positivity
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V628, S. 191-192
Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM)
In: Journal of clinical oncology / Englische Ausgabe. - Alexandria, Va : American Society of Clinical Oncology; Bd. 33.2015, 15 Suppl., Abs. 8511, insges. 1 S.
A pro-active follow-up with higher completeness can significantly influence survival data
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, P508, S. 155
Clinical outcome of primary CNS lymphoma comparing the setting of real-life with a clinical trial - a single centre experience of 95 patients
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V707, S. 211-212
Begutachteter Zeitschriftenartikel
Evolutionarily conserved signaling pathways - Acting in the shadows of acute myelogenous leukemia's genetic diversity
In: Clinical cancer research. - Philadelphia, Pa. [u.a.] : AACR, Bd. 21.2014, 2, S. 240-248, 2015
Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation - a single center experience
In: Annals of hematology : organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie. - Berlin : Springer, Bd. 94.2015, 2, S. 283-287
How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making. Correspondence
In: Journal of clinical oncology : JCO ; official journal of the American Society of Clinical Oncology. - Alexandria, Va : American Society of Clinical Oncology, Bd. 33.2015, 9, S. 1090-1091
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
In: Neurology : official journal of the American Academy of Neurology. - Hagerstown, Md : Lippincott Williams &amp;amp;amp;amp;amp; Wilkins, Bd. 84.2015, 12, S. 1242-1248
Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke
In: Acta neuropathologica. - Berlin : Springer, Bd. 129.2015, 2, S. 259-277
Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
In: Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal. - Basingstoke : Nature Publ. Group, Bd. 30.2016, 4, S. 991-995
Central venous catheter-related bloodstream infections in obese hematologic patients. Letter to the editor
In: Infection control and hospital epidemiology : the official journal of the Society for Healthcare Epidemiology of America. - Cambridge : Cambridge Univ. Press, Bd. 36.2015, 8, S. 995-996
Prediction of central venous catheterrelated bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS)
In: Annals of hematology : organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie. - Berlin : Springer, Bd. 94.2015, 9, S. 1451-1456
Weichteiltumoren - allgemein-klinische Aspekte ; chirurgische und medikamentöse Therapie
In: Der Onkologe : Organ der Deutschen Krebsgesellschaft e.V. - Berlin : Springer, Bd. 21.2015, 12, S. 1147-1161
Epo-induced erythroid maturation is dependent on Plc[gamma]1 signaling
In: Cell death and differentiation. - Houndmills, Basingstoke : Nature Publishing Group, Bd. 22.2015, 6, S. 974-985
Buchbeitrag
Efficient analysis and reduction of magnetic near-field-coupling in mixed-signal PCBs via the reciprocity principle
In: Proceedings of IEEE International Symposium on Electromagnetic Compatibility and EMC Europe. - Piscataway, NJ : IEEE, S. 91-95, 2015
Nicht begutachteter Zeitschriftenartikel
Eine Ärztin mit großem Einsatz und bei Patienten und MItarbeitern gleichermaßen beliebt - Im Gedenken an Prof. Dr. med. Astrid Franke
In: UMMD aktuell : Informationen für Patienten, Mitarbeiter und Studierende des Universitätsklinikums Magdeburg A.ö.R. und der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg. - Magdeburg : Klinikumsvorstand, 1, S. 15, 2015
2014
Abstrakt
Distinct biological and transcriptional features of FLT3-ITD variants in vitro and in vivo
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, V641, S. 206
Epidemiological analysis of multidrug-resistant Gramnegative bacteria (MRGN) among haemato-oncological patients
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, P874, S. 292
G-PCNSL-SG-1 randomised phase III trial of high-dose methotrexate with or without whole-brain radiotherapy for primary central nervous system lymphoma (PCNSL) - long-term follow-up
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, V122, S. 33
Impact of cold shock protein Ybx1 on hematopoietic stem cell development and function
In: Haematologica, the hematology journal : official organ of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 99.2014, Suppl.1, S. 175-176
Rapid induction of cytological remission by bendamustine in a rare case of T-PLL with leukostasis symptoms
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, P787, S. 258
Overexpression of the Cell Division Cycle 25C phosphatase in a two-hit-model of acute myeloid leukemia (AML) suppresses apoptosis upon cytotoxic treatment
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, P417, S. 125
Mathematical modelling of neutropenia of AML patients treated with chemotherapy
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, P501, S. 159
Prediction of central venous catheter- (CVC-) related bloodstream infections (CRBSIs) in cancer patients (pts) using the Infection Probability Score (IPS): first results from the SECRECY registry
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, V301, S. 94
JAK2V617F mutation is sufficient for autocrine induction of IP-10 in hematopoietic cells
In: Oncology research and treatment. - Basel : Karger; Bd. 37.2014, Suppl. 5, V618, S. 199
Begutachteter Zeitschriftenartikel
DAPK-HSF1 interaction as a positive-feedback mechanism stimulating TNF-induced apoptosis in colorectal cancer cells
In: Journal of cell science : Company of Biologists. - Cambridge : Company of Biologists Limited, Bd. 127.2014, 24, S. 5273-5287
Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events - the somatic burden score
In: Supportive care in cancer. - Berlin : Springer, Bd. 22.2014, 11, S. 3089-3099
Allogeneic stem cell transplantation for mantle cell lymphoma - final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
In: Annals of hematology. - Berlin : Springer, Bd. 93.2014, 9, S. 1587-1597
Multidrug-resistant gram-negative bacteria in hematology and oncology
In: Infection control and hospital epidemiology. - New York, NY : JSTOR, Bd. 35.2014, 9, S. 1203-1204
The incidence of norovirus infections in cancer patients shows less seasonal variability compared to patients with other diseases. Letter to the editor
In: Annals of hematology. - Berlin : Springer, Bd. 93.2014, 5, S. 889-890
Clinically relevant doses of FLT3-kinase inhibitors Quizartinib and Midostaurin do not impair T-cell reactivity and function
In: Haematologica, the hematology journal : official organ of the European Hematology Association. - Pavia : Ferrata Storti Foundation; Bd. 99.2014, 6, S. e90-e93
2013
Abstrakt
A case of acute myeloid leucaemia after EHEC infection
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P565, S. 166
Allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
In: Bone marrow transplantation. - London : Nature Publishing Group; Bd. 48.2013, Suppl.2s, R1531, S. S541
Health-related quality of life and distress in patients with systemic malignancies stratified by age: AYA patients have the worst mental health
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, V399, S. 108-109
The Magdeburg model of care for adolescents and young adults with cancer (MC AYA): A pilot approach
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P552, S. 162
Successful treatment of recurrent Desmoid fibromatosis in an adult using low dose chemotherapy with methotrexate and vinblastine
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P819, S. 249
Epidemiological data on norovirus infections in cancer patients, 2009-2012
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P271, S. 82
Begutachteter Zeitschriftenartikel
A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 27.2013, insges. 10 S.
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 27.2013, 8, S. 1628-1636
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
In: The journal of experimental medicine. - New York, NY : Rockefeller Univ. PressThe journal of experimental medicine <New York, NY>, Bd. 210.2013, 1, S. 15-22
Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis
In: International journal of biochemistry &amp;amp;amp;amp;amp; cell biology. - Amsterdam : Elsevier, Bd. 45.2013, 8, S. 1720-1729
Caught by an acute leukaemia: Facing patients' own experiences
In: Leukemia research. - Amsterdam : Elsevier, Bd. 37.2013, 5, S. 481-482
Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities
In: Cell communication and signaling. - London : Biomed Central; Bd. 11.2013, 1, Art.-Nr. 63, insges. 16 S.
Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells. Letter to the editor
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 27.2013, 7, S. 1567-1570
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
In: Journal of hematology &amp;amp;amp;amp;amp; oncology. - London : Biomed Central, Bd. 6.2013, insges. 6 S.
Nicht begutachteter Zeitschriftenartikel
Maligne Lymphome - Diagnostik und Therapie
In: Tumorzentrum aktuell // Tumorzentrum Magdeburg/Sachsen-Anhalt. - Magdeburg : Tumorzentrum, Bd. 10.2013, 1, S. 24-28
2012
Anderes Material
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL) - experience from the G-PCNSL-SG1 trial
In: Annals of oncology: official journal of the European Society for Medical Oncology - Oxford: Oxford Univ. Press, Bd. 23.2012, 9, S. 2374-2380; http://dx.doi.org/10.1093/annonc/mdr627
Artikel in Zeitschrift
Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression
In: Cell communication and signaling - London: Biomed Central, Bd. 10.2012, Artikel-Nr. 19, insges. 15 S.; http://dx.doi.org/10.1186/1478-811X-10-19
Begutachteter Zeitschriftenartikel
Strukturierte psychoonkologische Kurzintervention für Eltern Adoleszenter und junger Erwachsener (AYA) mit malignen hämatologischen Erkrankungen: eine randomisierte klinische Studie
In: Tumorzentrum aktuell // Tumorzentrum Magdeburg/Sachsen-Anhalt. - Magdeburg : Tumorzentrum, Bd. 9.2012, 1, S. 30-35
Aktuelle und neue Therapieoptionen bei myeloproliferativen Erkrankungen
In: Tumorzentrum aktuell // Tumorzentrum Magdeburg/Sachsen-Anhalt. - Magdeburg : Tumorzentrum, Bd. 9.2012, 1, S. 21-29
Originalartikel in begutachteter internationaler Zeitschrift
High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard
In: Journal of liquid chromatography &amp;amp;amp;amp;amp; related technologies. - Philadelphia, Pa. : Taylor &amp;amp;amp;amp;amp; Francis, Bd. 35.2012, 17, S. 2503-2510
3,4-Diarylmaleimides - a novel class of kinase inhibitors - effectively induce apoptosis in FLT3-ITD-dependent cells
In: Annals of hematology. - Berlin : Springer, Bd. 91.2012, 3, S. 331-344
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
In: Blood cancer journal. - London [u.a.] : Nature Publishing Group, Bd. 2.2012, 3, insges. 10 S.
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells
In: PLoS one. - Lawrence, Kan : PLoS, Bd. 7.2012, 7, insges. 16 S.
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 26.2012, 9, S. 2061-2068
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation
In: British journal of haematology. - Oxford [u.a.] : Wiley-Blackwell, Bd. 157.2012, 4, S. 483-492
2011
Originalartikel in begutachteter internationaler Zeitschrift
Rethinking bioactivity of FLT3 inhibitors
In: Blood. - Washington, DC : American Society of Hematology, Bd. 117.2011, 12, S. 3247-3248
Beyond diagnosis: subjective theories of illness in adult patients with acute myeloid leukemia
In: Hematology. - London [u.a.] : Maney, Bd. 16.2011, 1, S. 5-13
2010
Originalartikel in begutachteter internationaler Zeitschrift
Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
In: Journal of clinical oncology . - Alexandria, Va. : American Society of Clinical Oncology, Bd. 28.2010, 28, S. 4339-4345
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
In: Leukemia . - Basingstoke : Nature Publ. Group, Bd. 24.2010, 7, S. 1299-1301
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
In: Journal of clinical oncology . - Alexandria, Va. : American Society of Clinical Oncology, Bd. 28.2010, 34, S. 5074-5080
FLT3 as a therapeutic target in AML: still challenging after all these years
In: Blood . - Washington, DC : American Society of Hematology, Bd. 116.2010, 24, S. 5089-5102
Severe paraneoplastic pemphigus in a patient with follicular lymphoma
In: European journal of haematology . - Oxford : Wiley-Blackwell, Bd. 84.2010, 4, S. 365, insges. 1 S.
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-[gamma]1-driven activation of mTOR/p70S6-kinase pathway
In: Oncogene . - Basingstoke : Nature Publ. Group, Bd. 29.2010, 5, S. 739-751
Originalartikel in begutachteter nationaler Zeitschrift
Molekularpathologie von Sarkomen: Erste Ergebnisse des Sarkomforschungsverbundes KoSar
In: Der Pathologe : Organ der Deutschen Abteilung der Internationalen Akademie für Pathologie, der Deutschen, der Österreichischen und der Schweizerischen Gesellschaft für Pathologie und des Berufsverbandes Deutscher Pathologen. - Heidelberg : Springer-Medizin-Verl; Bd. 31.2010, Suppl.2, S. 211-214
2009
Nicht begutachteter Zeitschriftenartikel
Krebspatienten brauchen ein individuelles psychologisches Angebot - 2. Magdeburger Psychoonkologisches Kolloquium
In: Ärzteblatt Sachsen-Anhalt . - Magdeburg : Ärztekammer Sachsen-Anhalt, Bd. 20.2009, 4, S. 50-54
Originalartikel in begutachteter internationaler Zeitschrift
A Novel Molecular Mechanism of Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukaemia.
In: Blood 2009 Apr 23;113(17):4063-73. Epub 2009 Jan 14.
Identification of a Novel Type of ITD Mutations Located in Non-Juxtamembrane Domains of the FLT3 Tyrosine Kinase Receptor.
In: Blood 2009 Apr 23;113(17):4074-7. Epub 2008 May 15.
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma
In: British journal of haematology . - Oxford [u.a.] : Wiley-Blackwell, Bd. 147.2009, 1, S. 97-101
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro
In: British journal of haematology . - Oxford [u.a.] : Wiley-Blackwell, Bd. 144.2009, 6, S. 865-874
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
In: Blood . - Washington, DC : American Society of Hematology, Bd. 114.2009, 12, S. 2386-2392
2008
Originalartikel in begutachteter internationaler Zeitschrift
Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment.
In: Blood 111(3):1039-43, 2008
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukaemia.
In: Leuk Res. 2008 Nov;32(11):1698-708. Epub 2008 Jun 16.
Entwicklung von Tyrosinkinase-Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutische Targets.
In: Pharm Unserer Zeit. 2008;37(5):394-403.
LS104, a non ATP-competitive small molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2-V617F positive cells.
In: Mol Cancer Ther 7(5): 1176-1184, 2008.
2007
Originalartikel in begutachteter internationaler Zeitschrift
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
In: Cancer 110:1509-19, 2007.
Co-expression of tyrosine kinase receptors in gastric adenocarcinoma ¿ a rationale for a new molecular targeting strategy?
In: World J Gastroenterol 13(26):3605-9, 2007.
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukaemia in myeloid blast crisis.
In: Cancer 109:1543-9, 2007.
A neoepitope generated by a FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T-cells.
In: Blood 109(7):2985-2988, 2007.
Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
In: Blood 109:4686-92, 2007
Results of a multicenter phase II trial for older patients with c-kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and Imatinib (IM).
In: Cancer 109(5):907-14, 2007.
Cross-inhibition of IFN-induced signal transduction by GM-CSF through a block in STAT1- activation.
In: J Interferon Cytokine Res 27(11):947-59, 2007.
2006
Originalartikel in begutachteter internationaler Zeitschrift
Five-Year Follow-up of Imatinib Therapy for Newly Diagnosed Chronic Myeloid Leukemia in Chronic-Phase Shows Sustained Responses and High Overall Survival.
In: New England Journal of Medicine 355:2408-17, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
In: Clinical Cancer Research 1;12(15):4628-35, 2006.
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia (AML) by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
In: Blood 107(1):293-300, 2006.
Novel Bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinases.
In: Journal of Medicinal Chemistry 49: 3101-3115, 2006.
Histone deacetylase inhibition by valproic acid downregulates c-FLIP and sensitizes hepatoma cells towards CD95- and TRAIL-receptor mediated apoptosis and chemotherapy.
In: Oncology Reports 15: 227-230, 2006.
- Hämatologie/Onkologie
- Innere Medizin
- Onkogene Signaltransduktion
- bei gutartigen und bösartigen hämatologischen Erkrankungen;
- bei Leukämien, myelodysplastischem Syndrom, myeloproliferativen Neoplasien, Lymphomen, Multiplem Myelom (Plasmozytom);
- bei Tumorerkrankungen;
- bei Weichteilsarkomen;
- bei sogenanntem CUP -Syndrom.
Beratung zur hämatopoetischen Stammzelltransplantation
1980 - 1981 | Rumänisch Studium an der Universität Craiova, Rumänien |
1981 - 1982 | Medizinstudium an der Universität Cluj, Rumänien |
1982 - 1983 | Medizinstudium an der Georg-August-Universität Göttingen |
1983 - 1984 | Medizinstudium an der Medizinischen Hochschule Hannover |
1985 | Stipendiat der Soltenborn-Stiftung |
1984 - 1987 | Medizinstudium an der Georg-August-Universität Göttingen |
1987 - 1988 | Praktisches Jahr: Tufts University, Boston, USA (Stipendiat des "Biomedical Sciences Exchange Program between The United States and West Germany"); Krh. Seesen; Krh. Bad Harzburg |
AKADEMISCHE GRADE
1988 | Promotion zum Dr. med. an der Georg-August-Universität Göttingen, Bewertung: Magna cum laude |
2000 | Habilitation und venia legendi für das Fach "Innere Medizin" am Fachbereich Medizin der Johannes Gutenberg-Universität Mainz (Molekulare Untersuchungen zur Signaltransduktion IFN-induzierter Gene in leukämischen und normalen hämatopoetischen Zellen) |
BERUFLICHER WERDEGANG
10/1988 - 3/1990 | DFG-Postdoktorandenstipendium in der klinischen Arbeitsgruppe der Max-Planck-Gesellschaft an der Medizinischen Universitätsklinik Göttingen (Leiter: Prof. Dr. K. Pfizenmaier) |
4/1990 - 9/1990 | "Postdoctoral Research Fellowship am "Hospital for Sick Children , Toronto, Kanada (Prof. Dr. B. Williams) |
10/1990 - 11/1996 | Assistent an der III. Medizinischen Klinik der Johannes-Gutenberg-Universität Mainz (Direktor: Prof. Dr. C. Huber) |
1/1995 - 12/1995 | "Clinical Fellowship in Hämatologie/Onkologie am "Department for Hematology and Medical Oncology , Cleveland Clinic Foundation, Cleveland, USA |
5/1996 | Facharzt-Anerkennung Arzt für Innere Medizin |
12/1996 - 6/2008 | Oberarzt und Arbeitsgruppenleiter an der Medizinischen Klinik der Johannes Gutenberg-Universität Mainz. Aufbau und Leitung des wissenschaftlichen Labors für Onkogene Signaltransduktion. |
1/1998 | Anerkennung Hämatologie und Internistische Onkologie |
3/2001- 4/2004 | Medical Director und Vertreter von Prof. Dr. med. Christoph Huber an der III. Medizinischen Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz. Strategisches, operatives, wirtschaftliches, personalführendes und administratives "Management" der III. Medizinischen Klinik und Poliklinik. |
3/2005 | Berufung auf eine Professur (W2) für "Leukämie- und Tumorforschung" im Fachbereich Medizin der Johannes Gutenberg-Universität Mainz an der III. Medizinischen Klinik und Poliklinik (Stiftungsprofessur). |
Seit 5/2009 | Univ.-Professor (W3) und Direktor der Klinik für Hämatologie und Onkologie an der Otto-von-Guericke-Universität Magdeburg |